136 related articles for article (PubMed ID: 30273184)
1. The Partnership for Accelerating Cancer Therapies.
Baker RG; Hoos AX; Adam SJ; Wholley D; Doroshow JH; Lowy DR; Tabak LA; Collins FS
Cancer J; 2018; 24(3):111-114. PubMed ID: 30273184
[TBL] [Abstract][Full Text] [Related]
2. Budgets up at NIH, NCI, and FDA.
Cancer Discov; 2014 Mar; 4(3):263. PubMed ID: 24596185
[TBL] [Abstract][Full Text] [Related]
3. Cancer research: evaluating the sequester's impact.
Schmidt C
J Natl Cancer Inst; 2013 Aug; 105(16):1160-1. PubMed ID: 23904503
[No Abstract] [Full Text] [Related]
4. Congress Approves Increase in Cancer Funding.
Cancer Discov; 2021 Mar; 11(3):524. PubMed ID: 33483379
[TBL] [Abstract][Full Text] [Related]
5. Five strategies for accelerating the war on cancer in an era of budget deficits.
Doroshow JH; Croyle RT; Niederhuber JE
Oncologist; 2009 Feb; 14(2):110-6. PubMed ID: 19147688
[TBL] [Abstract][Full Text] [Related]
6. Stone Soup: commentary on "Five strategies for accelerating the war on cancer in an era of budget deficits".
Young RC
Oncologist; 2009 Feb; 14(2):117-8. PubMed ID: 19211619
[No Abstract] [Full Text] [Related]
7. The flat-funding years and the National Cancer Institute: consequences for cancer research.
Hitt E
Mol Oncol; 2008 Dec; 2(4):290-2. PubMed ID: 19383350
[TBL] [Abstract][Full Text] [Related]
8. Bottom-line reality tempers cancer researchers' excitement.
Benowitz S
J Natl Cancer Inst; 2009 Sep; 101(17):1166-9. PubMed ID: 19679851
[No Abstract] [Full Text] [Related]
9. Congress OKs $2 Billion Boost for the NIH.
Cancer Discov; 2017 Jul; 7(7):657. PubMed ID: 28522683
[TBL] [Abstract][Full Text] [Related]
10. National Cancer Institute Formulary: A Public-Private Partnership Providing Investigators Access to Investigational Anticancer Agents.
Cristofaro JV; Ansher SS; Zwiebel JA; Ivy P; Conley B; Abrams JS; Doroshow JH
Clin Pharmacol Ther; 2017 May; 101(5):616-618. PubMed ID: 27981567
[TBL] [Abstract][Full Text] [Related]
11. Stimulus funds force hard look at comparative effectiveness research.
Tuma RS
J Natl Cancer Inst; 2009 Aug; 101(15):1036-9. PubMed ID: 19638502
[No Abstract] [Full Text] [Related]
12. Cancer costs.
Nature; 2013 Mar; 495(7440):142. PubMed ID: 23495394
[No Abstract] [Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.
Menetski JP; Hoffmann SC; Cush SS; Kamphaus TN; Austin CP; Herrling PL; Wagner JA
Clin Pharmacol Ther; 2019 Apr; 105(4):829-843. PubMed ID: 30648736
[TBL] [Abstract][Full Text] [Related]
15. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
Khleif SN; Doroshow JH; Hait WN;
Clin Cancer Res; 2010 Jul; 16(13):3299-318. PubMed ID: 20501613
[TBL] [Abstract][Full Text] [Related]
16. Budget cuts and the plight of postdocs.
Goozner M
J Natl Cancer Inst; 2013 Feb; 105(3):153-4. PubMed ID: 23334223
[No Abstract] [Full Text] [Related]
17. Economic Evaluations in National Cancer Institute-Sponsored Network Cancer Clinical Trials.
Nghiem VT; Vaidya R; Lyman GH; Hershman DL; Ramsey SD; Unger JM
Value Health; 2020 Dec; 23(12):1653-1661. PubMed ID: 33248521
[TBL] [Abstract][Full Text] [Related]
18. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
19. AACR-FDA-NCI cancer biomarkers collaborative.
Yu LR; Veenstra TD
Expert Rev Mol Diagn; 2007 Sep; 7(5):507-9. PubMed ID: 17892359
[TBL] [Abstract][Full Text] [Related]
20. Launching a plan for the Cancer Moonshot.
The Lancet
Lancet; 2016 Sep; 388(10050):1130. PubMed ID: 27650078
[No Abstract] [Full Text] [Related]
[Next] [New Search]
